Drug Profile
Research programme: pain therapeutics and companion diagnostics - Genentech/Xenon Pharmaceuticals
Alternative Names: XEN-907Latest Information Update: 02 Mar 2023
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Developer Genentech; Xenon Pharmaceuticals
- Class Analgesics; Diagnostic agents; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 02 Mar 2023 Discontinued - Preclinical for Pain in USA (PO)
- 02 Mar 2023 Discontinued for Pain (Diagnosis) in USA (PO)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Pain in USA (PO)